EMERYVILLE, Calif. , April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66 th Annual Meeting, April 26 to May 3, 2014 , in Philadelphia, PA.
EMERYVILLE, Calif. , April 15, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. ( Adamas ) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share.
ADAMAS PHARMACEUTICALS ANNOUNCES PRICING OF ITS INITIAL PUBLIC OFFERING Emeryville, Calif., April 9, 2014 – Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public
Forest Laboratories and Adamas Pharmaceuticals Announce Forest's Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer's Disease New York, NY and Emeryville, CA - March 04, 2014 - Forest Laboratories, Inc.
Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704 EMERYVILLE, CA, January 9, 2014 - Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease Emeryville, Calif., June 18, 2013 - Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102
Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCL ER) Program Emeryville, Calif., April 22, 2013 - Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from Its Nurelin™ Program at American Academy of Neurology Conference Emeryville, Calif., March 20, 2013 - Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin™ (amantadine HCl extended release capsules)